Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Francesca Fairhurst"'
Autor:
Marco Vincenzo Lenti, Vivien Dolby, Tanya Clark, Veronica Hall, Suzanne Tattersall, Francesca Fairhurst, Catherine Kenneth, Rachael Walker, Karen Kemp, Simon Borg‐Bartolo, Jimmy K. Limdi, Jo Taylor, Tristan Townsend, Sree Subramanian, Daniel Storey, Arash Assadsangabi, Catherine Stansfield, Paul Smith, Debra Byrne, Annalisa De Silvestri, Christian P. Selinger
Publikováno v:
Alimentary Pharmacology & Therapeutics. 55:856-866
Autor:
Simon Borg-Bartolo, Suzanne Tattersall, Daniel Storey, Jimmy K. Limdi, Paul Smith, Francesca Fairhurst, Rachael Walker, Christian P. Selinger, S Subramanian, Veronica Hall, Jo Taylor, Catherine Kenneth, Marco Vincenzo Lenti, Vivien Dolby, Arash Assadsangabi, Debra Byrne, Tristan Townsend, Catherine Stansfield, Karen Kemp, Tanya Clark
Publikováno v:
Posters.
Background Ustekinumab was approved by NICE in 2016 for adults with moderate to severe CD. Real world data are required to establish effectiveness of therapy where restrictive inclusion and exclusion criteria from trials are not routinely applied. Me
Autor:
George Lipscomb, Suzanne Tattersall, Zandile Ndlovu, Salil Singh, Shahd Ahmed, Veronica Hall, Francesca Fairhurst
Publikováno v:
Posters.
Introduction The consultation is a pivotal event in the clinician/patient relationship, defined as the act of seeking assistance from a physician in order to benefit their patient. However, studies support that in only 23% of consultations was the pa
Autor:
Salil Singh, Catherine Stansfield, Eleanor Liu, Paul Smith, Anna Carter, Alex Johnston, Belle Gregg, Marco Vincenzo Lenti, Sreedhar Subramanian, Scott Levison, PJ Hamlin, Chris Probert, Daniel Storey, Ben Crooks, Elena Eliadou, Catherine Kenneth, Christian P. Selinger, Jimmy K. Limdi, Robert P. Willert, Suzanne Tattersall, Francesca Fairhurst, Arash Assadsangabi, Karen Kemp
Publikováno v:
DIGESTIVE AND LIVER DISEASE
BACKGROUND Real-life data on vedolizumab effectiveness in inflammatory bowel disease (IBD) are still emerging. Data on the comparative safety of the gut selective profile are of particular interest. AIMS To assess clinical outcome and safety in IBD p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e2b5a6d4bff8745c57b42ae75773b4f